
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="article-commentary"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32457598</article-id><article-id pub-id-type="pmc">7225266</article-id><article-id pub-id-type="doi">10.3389/fnagi.2020.00127</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>General Commentary</subject></subj-group></subj-group></article-categories><title-group><article-title>Commentary: Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dzianok</surname><given-names>Patrycja</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/920166/overview"/></contrib><contrib contrib-type="author"><name><surname>Kublik</surname><given-names>Ewa</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/141081/overview"/></contrib></contrib-group><aff><institution>Laboratory of Emotions Neurobiology, Nencki Institute of Experimental Biology PAS</institution>, <addr-line>Warsaw</addr-line>, <country>Poland</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Robert Petersen, Central Michigan University, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Boon-Seng Wong, Singapore Institute of Technology, Singapore</p></fn><corresp id="c001">*Correspondence: Patrycja Dzianok <email>p.dzianok@nencki.edu.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>12</volume><elocation-id>127</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Dzianok and Kublik.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Dzianok and Kublik</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="d35e106" xlink:href="31331998" ext-link-type="pubmed" journal-id="J Neurosci" journal-id-type="nlm-ta" vol="39" page="7408">A commentary on <article-title>Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk</article-title> by Huang, Y. A., Zhou, B., Nabet, A. M., Wernig, M., and S&#x000fc;dhof, T. C. (2019). J. Neurosci. 39, 7408&#x02013;7427. doi: <object-id>10.1523/JNEUROSCI.2994-18.2019</object-id></related-article><kwd-group><kwd>Alzheimer's disease</kwd><kwd>APOE</kwd><kwd>neurodegeneration</kwd><kwd>synapse</kwd><kwd>risk-genes</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="26"/><page-count count="3"/><word-count count="2224"/></counts></article-meta></front><body><p>Alzheimer's disease (AD) is a neurodegenerative condition that inevitably impairs cognitive functions and influences a patient's behavior, mood, and self-reliance. Due to demographic changes, AD and other age-associated diseases have become increasingly common and burdensome for families, as well as entire societies. It is extremely important that we learn more about specific mechanisms that can be linked to the development of the disease. The main symptoms of AD, observed in the central nervous system, are brain atrophy and loss of neurons and synapses. They are believed to result from excessive aggregation of tau protein and amyloid plaques (composed of &#x000df;-amyloid). However, neither the initial cause nor the detailed chain of events that lead to this type of neurodegeneration are known. No deterministic genes were identified for late-onset Alzheimer's disease (LOAD), but several risk genes seem to be involved in its pathogenesis. The gene coding apolipoprotein E (<italic>APOE</italic>) is the best-known and has the strongest association with AD development. AD probability decreases in carriers of the e2 variant of the <italic>APOE</italic> gene (<italic>APOE-</italic>e2), whereas <italic>APOE</italic>-e4 is believed to be a strong risk factor (Strittmatter et al., <xref rid="B24" ref-type="bibr">1993</xref>) and is associated with overall cognitive impairment and synapse loss (see review by Selkoe, <xref rid="B21" ref-type="bibr">2002</xref>).</p><p>Few hypotheses have been proposed in the literature explaining possible mechanisms by which <italic>APOE</italic> could affect the brain and promote AD. ApoE in the brain is mostly expressed by astrocytes and microglia and is thought to be involved in the metabolism and clearance of lipoproteins (see Fernandez et al., <xref rid="B6" ref-type="bibr">2019</xref> for review). Astrocytes play a vital role in the internalization and degradation of extracellular beta-amyloid (A&#x003b2;), the component which forms plaques that are believed to be involved in AD neurodegeneration (Serrano-Pozo et al., <xref rid="B22" ref-type="bibr">2011</xref>; Ries and Sastre, <xref rid="B19" ref-type="bibr">2016</xref>, see also review by Haass and Selkoe, <xref rid="B7" ref-type="bibr">2017</xref>; Fernandez et al., <xref rid="B6" ref-type="bibr">2019</xref>). The <italic>APOE</italic>-e4 variant was shown to be least effective in degradation of A&#x003b2; (Castellano et al., <xref rid="B2" ref-type="bibr">2012</xref>).</p><p>Another hypothesis points to the fact that ApoE variants have different binding properties (Calandra et al., <xref rid="B1" ref-type="bibr">2011</xref>) to the receptors that regulate intracellular signaling (Ohkubo et al., <xref rid="B16" ref-type="bibr">2001</xref>; Qiu et al., <xref rid="B18" ref-type="bibr">2004</xref>). This hypothesis was first addressed by Huang et al. (<xref rid="B9" ref-type="bibr">2017</xref>) and again in a replication and control study published last year in the Journal of Neuroscience (Huang et al., <xref rid="B8" ref-type="bibr">2019</xref>). Their research was conducted on stem cell-derived human neurons cultured without glial cells. Results of the experiments (Huang et al., <xref rid="B8" ref-type="bibr">2019</xref>) showed that even in the absence of glial cells ApoE strongly and diversely influenced signal transduction cascades in neurons, which led to intensification of amyloid precursor protein (APP) synthesis and, at the same time, to the formation of new synapses. The study revealed the synaptic paradox of the <italic>APOE</italic>-related risk of AD: surprisingly, it was <italic>APOE-</italic>e4, the gene variant that is linked to the highest risk of AD, that was most efficient in stimulating MAP signaling and in enhancing synaptogenesis.</p><p>The question arises: how is it possible to link these cell-level studies with the same ranking (<italic>APOE-</italic>e4 &#x0003e; <italic>APOE-</italic>e3 &#x0003e; <italic>APOE-</italic>e2) of negative impact on human brain function in AD. Results indicating enhanced APP synthesis are in agreement with studies showing higher levels of A&#x003b2; in brains of <italic>APOE</italic>-e4 carriers, examined post-mortem (Shinohara et al., <xref rid="B23" ref-type="bibr">2013</xref>), as well as <italic>in vivo</italic> studies using positron emission tomography (see review of Jack and Kepe, <xref rid="B10" ref-type="bibr">2013</xref>). However, a reported <italic>APOE</italic>-e4-related increase in synapse formation contradicted numerous findings indicating the highest loss of synapses and severity of cognitive decline in <italic>APOE-</italic>e4 carriers (Terry et al., <xref rid="B25" ref-type="bibr">1991</xref>; Selkoe, <xref rid="B21" ref-type="bibr">2002</xref>; Scheff et al., <xref rid="B20" ref-type="bibr">2006</xref>; Purro et al., <xref rid="B17" ref-type="bibr">2012</xref>; Chen et al., <xref rid="B3" ref-type="bibr">2018</xref>). It appears that the link between <italic>APOE</italic> isoforms and neuronal and synaptic dysfunction observed in AD comprises multiple, seemingly contradictory, mechanisms. Huang et al. (<xref rid="B8" ref-type="bibr">2019</xref>), and previously Lin et al. (<xref rid="B13" ref-type="bibr">2018</xref>), showed an <italic>APOE</italic>-e4 related increase in the number of synapses in isolated neurons. On the other hand <italic>in vivo</italic> research has demonstrated strong evidence of synapse loss related to memory and cognitive impairment, which characterize dementia and neurodegeneration. The direct effect of <italic>APOE-</italic>e4 on neurons can be modulated by the interplay of many factors, including the activity of glial cells (mainly astrocytes and microglia) and other risk-genes. Moreover, it was shown that neurons need astrocytes and microglia to eliminate redundant synapses (Lee and Chung, <xref rid="B12" ref-type="bibr">2019</xref>). Maintaining proper synapse number is a crucial process in learning and memory and thus any changes may disrupt the cells' homeostasis and lead to neurodegenerative diseases like AD. <italic>APOE-</italic>e4 was shown to inhibit synaptic pruning, realized by astrocyte phagocytosis, whereas <italic>APOE</italic>-e2 promoted it Chung et al. (<xref rid="B4" ref-type="bibr">2016</xref>). <italic>APOE</italic> has a strong impact on lipoprotein (and cholesterol) homeostasis and synaptic stability maintenance, with <italic>APOE-</italic>e4 having the most negative impact on the brain. <italic>APOE</italic>-e4 limits the astrocytes' ability to recycle and clear extracellular cholesterol (Fernandez et al., <xref rid="B6" ref-type="bibr">2019</xref>) and leads to its accumulation and an increase of A&#x003b2; (Strittmatter et al., <xref rid="B24" ref-type="bibr">1993</xref>) related to synaptic dysfunction (Purro et al., <xref rid="B17" ref-type="bibr">2012</xref>). Human astrocytes with <italic>APOE-</italic>e4 showed accumulation of cholesterol and could not efficiently fulfill their role related to clearance of A&#x003b2; (Lin et al., <xref rid="B13" ref-type="bibr">2018</xref>).</p><p>Perhaps it is the initial higher number of synapses and APP in neurons with <italic>APOE</italic>-e4 that leads to an increase in toxic A&#x003b2; forms and impairs astrocytes' function, which can initiate the whole cascade of changes related to later loss of synapses and cognitive functions. It may indicate that, in the brains of <italic>APOE</italic>-e4 carriers, AD risks begin to accumulate from early developmental stages when too many synapses are formed and not enough of them are pruned (Chung et al., <xref rid="B4" ref-type="bibr">2016</xref>; Lin et al., <xref rid="B13" ref-type="bibr">2018</xref>; Huang et al., <xref rid="B8" ref-type="bibr">2019</xref>). Although, the <italic>APOE-</italic>e4 risk related to loss of cognitive functions is predominant for persons older than 50 years of age, people homozygous for <italic>APOE-</italic>e4 may experience the risk much earlier, just after 40 years of age (Liu et al., <xref rid="B14" ref-type="bibr">2010</xref>). Other studies point out that <italic>APOE-</italic>e4 could affect the brain even earlier, changing its structure, function and neurochemistry (see DiBattista et al., <xref rid="B5" ref-type="bibr">2016</xref> for review). <italic>APOE</italic>-e4 young carriers perform equally well or even much better in a variety of cognitive tasks compared to non-carriers (Mondadori et al., <xref rid="B15" ref-type="bibr">2007</xref>; Jochemsen et al., <xref rid="B11" ref-type="bibr">2012</xref>; DiBattista et al., <xref rid="B5" ref-type="bibr">2016</xref>). The effect is tried to be explained by antagonistic pleiotropy hypothesis: some genes may enhance fitness early in life but act adversely in elderly. They are still favored by natural selection since the survival of the species depends on young individuals (Tuminello and Han, <xref rid="B26" ref-type="bibr">2011</xref>; DiBattista et al., <xref rid="B5" ref-type="bibr">2016</xref>). Understanding the specific influence of <italic>APOE</italic>-e4 on neuronal signaling pathways throughout the lifespan may help us to identify early biomarkers and target therapy against AD in the future.</p><sec id="s1"><title>Author Contributions</title><p>PD wrote the first draft. EK critically edited and improved the manuscript. PD and EK read and approved the final version of the manuscript.</p></sec><sec id="s2"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by a grant from the National Science Centre in Poland 2018/31/N/HS6/03551.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calandra</surname><given-names>S.</given-names></name><name><surname>Tarugi</surname><given-names>P.</given-names></name><name><surname>Speedy</surname><given-names>H. E.</given-names></name><name><surname>Dean</surname><given-names>A. F.</given-names></name><name><surname>Bertolini</surname><given-names>S.</given-names></name><name><surname>Shoulders</surname><given-names>C. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk</article-title>. <source>J. Lipid Res.</source>
<volume>52</volume>, <fpage>1885</fpage>&#x02013;<lpage>1926</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.R017855</pub-id><pub-id pub-id-type="pmid">21862702</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellano</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Stewart</surname><given-names>F. R.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>DeMattos</surname><given-names>R. B.</given-names></name><name><surname>Patterson</surname><given-names>B. W.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Human apoE isoforms differentially regulate brain amyloid-&#x003b2; peptide clearance</article-title>. <source>Sci. Transl. Med</source>. <volume>3</volume>:<fpage>ra57</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3002156</pub-id><pub-id pub-id-type="pmid">21715678</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M. K.</given-names></name><name><surname>Mecca</surname><given-names>A. P.</given-names></name><name><surname>Naganawa</surname><given-names>M.</given-names></name><name><surname>Finnema</surname><given-names>S. J.</given-names></name><name><surname>Toyonaga</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>S. -F</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging</article-title>. <source>JAMA Neurol</source>. <volume>75</volume>, <fpage>1215</fpage>&#x02013;<lpage>1224</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2018.1836</pub-id><pub-id pub-id-type="pmid">30014145</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>W. S.</given-names></name><name><surname>Verghese</surname><given-names>P. B.</given-names></name><name><surname>Chakraborty</surname><given-names>C.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name><name><surname>Hyman</surname><given-names>B. T.</given-names></name><name><surname>Ulrich</surname><given-names>J. D.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>113</volume>, <fpage>10186</fpage>&#x02013;<lpage>10191</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1609896113</pub-id><pub-id pub-id-type="pmid">27559087</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiBattista</surname><given-names>A. M.</given-names></name><name><surname>Heinsinger</surname><given-names>N. M.</given-names></name><name><surname>Rebeck</surname><given-names>G. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Alzheimer's Disease genetic risk factor APOE-&#x003b5;4 also affects normal brain function</article-title>. <source>Curr. Alzheimer Res</source>. <volume>13</volume>, <fpage>1200</fpage>&#x02013;<lpage>1207</lpage>. <pub-id pub-id-type="doi">10.2174/1567205013666160401115127</pub-id><pub-id pub-id-type="pmid">27033053</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>C. G.</given-names></name><name><surname>Hamby</surname><given-names>M. E.</given-names></name><name><surname>McReynolds</surname><given-names>M. L.</given-names></name><name><surname>Ray</surname><given-names>W. J.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of APOE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer's Disease</article-title>. <source>Front. Aging Neurosci</source>. <volume>11</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2019.00014</pub-id><pub-id pub-id-type="pmid">30804776</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C.</given-names></name><name><surname>Selkoe</surname><given-names>D. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide</article-title>. <source>Nat. Rev. Mol. Cell Biol</source>. <volume>8</volume>, <fpage>101</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2101</pub-id><pub-id pub-id-type="pmid">17245412</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y. A.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Nabet</surname><given-names>A. M.</given-names></name><name><surname>Wernig</surname><given-names>M.</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>T. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Differential signaling mediated by ApoE2, ApoE3, and ApoE4 in human neurons parallels Alzheimer's Disease risk</article-title>. <source>J. Neurosci.</source>
<volume>39</volume>, <fpage>7408</fpage>&#x02013;<lpage>7427</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2994-18.2019</pub-id><pub-id pub-id-type="pmid">31331998</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y. A.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Wernig</surname><given-names>M.</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>T. C.</given-names></name></person-group> (<year>2017</year>). <article-title>ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and abeta secretion</article-title>. <source>Cell</source>
<volume>168</volume>, <fpage>427</fpage>&#x02013;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.12.044</pub-id><pub-id pub-id-type="pmid">28111074</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>C. R.</given-names><suffix>Jr.</suffix></name><name><surname>Barrio</surname><given-names>J. R.</given-names></name><name><surname>Kepe</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>Cerebral amyloid PET imaging in Alzheimer's disease</article-title>. <source>Acta Neuropathol</source>. <volume>126</volume>, <fpage>643</fpage>&#x02013;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-013-1185-7</pub-id><pub-id pub-id-type="pmid">24100688</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jochemsen</surname><given-names>H. M.</given-names></name><name><surname>Muller</surname><given-names>M.</given-names></name><name><surname>van der Graaf</surname><given-names>Y.</given-names></name><name><surname>Geerlings</surname><given-names>M. I.</given-names></name></person-group> (<year>2012</year>). <article-title>APOE epsilon4 differentially influences change in memory performance depending on age. The SMART-MR study</article-title>. <source>Neurobiol. Aging</source>
<volume>33</volume>, <fpage>832 e15</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.07.016</pub-id><pub-id pub-id-type="pmid">21908077</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E.</given-names></name><name><surname>Chung</surname><given-names>W. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Glial control of synapse number in healthy and diseased brain</article-title>. <source>Front. Cell Neurosci</source>. <volume>13</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2019.00042</pub-id><pub-id pub-id-type="pmid">30814931</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y. T.</given-names></name><name><surname>Seo</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Feldman</surname><given-names>H. M.</given-names></name><name><surname>Wen</surname><given-names>H. L.</given-names></name><name><surname>Penney</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's Disease phenotypes in human iPSC-derived brain cell types</article-title>. <source>Neuron</source>
<volume>98</volume>, <fpage>1141</fpage>&#x02013;<lpage>1154</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2018.05.008</pub-id><pub-id pub-id-type="pmid">29861287</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Pardo</surname><given-names>L. M.</given-names></name><name><surname>Schuur</surname><given-names>M.</given-names></name><name><surname>Sanchez-Juan</surname><given-names>P.</given-names></name><name><surname>Isaacs</surname><given-names>A.</given-names></name><name><surname>Sleegers</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>The apolipoprotein E gene and its age-specific effects on cognitive function</article-title>. <source>Neurobiol. Aging</source>. <fpage>1831</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2008.09.015</pub-id><pub-id pub-id-type="pmid">19004527</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondadori</surname><given-names>C. R.</given-names></name><name><surname>de Quervain</surname><given-names>D. J.</given-names></name><name><surname>Buchmann</surname><given-names>A.</given-names></name><name><surname>Mustovic</surname><given-names>H.</given-names></name><name><surname>Wollmer</surname><given-names>M. A.</given-names></name><name><surname>Schmidt</surname><given-names>C. F.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers</article-title>. <source>Cereb Cortex</source>. <volume>17</volume>, <fpage>1934</fpage>&#x02013;<lpage>1947</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhl103</pub-id><pub-id pub-id-type="pmid">17077159</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkubo</surname><given-names>N.</given-names></name><name><surname>Mitsuda</surname><given-names>N.</given-names></name><name><surname>Tamatani</surname><given-names>M.</given-names></name><name><surname>Yamaguchi</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>Y. D.</given-names></name><name><surname>Ogihara</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>3046</fpage>&#x02013;<lpage>3053</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M005070200</pub-id><pub-id pub-id-type="pmid">11042199</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purro</surname><given-names>S. A.</given-names></name><name><surname>Dickins</surname><given-names>E. M.</given-names></name><name><surname>Salinas</surname><given-names>P. C.</given-names></name></person-group> (<year>2012</year>). <article-title>The secreted Wnt antagonist Dickkopf-1 is required for amyloid &#x003b2;-mediated synaptic loss</article-title>. <source>J. Neurosci</source>. <volume>32</volume>, <fpage>3492</fpage>&#x02013;<lpage>3498</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4562-11.2012</pub-id><pub-id pub-id-type="pmid">22399772</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Z.</given-names></name><name><surname>Hyman</surname><given-names>B. T.</given-names></name><name><surname>Rebeck</surname><given-names>G. W.</given-names></name></person-group> (<year>2004</year>). <article-title>Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>34948</fpage>-<lpage>34956</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M401055200</pub-id><pub-id pub-id-type="pmid">15169786</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ries</surname><given-names>M.</given-names></name><name><surname>Sastre</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanisms of A&#x003b2; clearance and degradation by glial cells</article-title>. <source>Front. Aging Neurosci</source>. <volume>8</volume>:<fpage>160</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2016.00160</pub-id><pub-id pub-id-type="pmid">27458370</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheff</surname><given-names>S. W.</given-names></name><name><surname>Price</surname><given-names>D. A.</given-names></name><name><surname>Schmitt</surname><given-names>F. A.</given-names></name><name><surname>Mufson</surname><given-names>E. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment</article-title>. <source>Neurobiol. Aging</source>
<volume>27</volume>, <fpage>1372</fpage>&#x02013;<lpage>1384</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.012</pub-id><pub-id pub-id-type="pmid">16289476</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>D. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Alzheimer's disease is a synaptic failure</article-title>. <source>Science</source>
<volume>298</volume>, <fpage>789</fpage>&#x02013;<lpage>791</lpage>. <pub-id pub-id-type="doi">10.1126/science.1074069</pub-id><pub-id pub-id-type="pmid">12399581</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Pozo</surname><given-names>A.</given-names></name><name><surname>Frosch</surname><given-names>M. P.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Hyman</surname><given-names>B. T.</given-names></name></person-group> (<year>2011</year>). <article-title>Neuropathological alterations in Alzheimer disease</article-title>. <source>Cold Spring Harb. Perspect. Med</source>. <volume>2011</volume>:<fpage>a006189</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a006189</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinohara</surname><given-names>M.</given-names></name><name><surname>Petersen</surname><given-names>R. C.</given-names></name><name><surname>Dickson</surname><given-names>D. W.</given-names></name><name><surname>Bu</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Brain regional correlation of amyloid-&#x003b2; with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-&#x003b2; accumulation</article-title>. <source>Acta Neuropathol</source>. <volume>125</volume>, <fpage>535</fpage>&#x02013;<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-013-1086-9</pub-id><pub-id pub-id-type="pmid">23371365</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strittmatter</surname><given-names>W. J.</given-names></name><name><surname>Saunders</surname><given-names>A. M.</given-names></name><name><surname>Schmechel</surname><given-names>D.</given-names></name><name><surname>Pericak-Vance</surname><given-names>M.</given-names></name><name><surname>Enghild</surname><given-names>J.</given-names></name><name><surname>Salvesen</surname><given-names>G. S.</given-names></name><etal/></person-group>. (<year>1993</year>). <article-title>Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>90</volume>, <fpage>1977</fpage>&#x02013;<lpage>1981</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.90.5.1977</pub-id><pub-id pub-id-type="pmid">8446617</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terry</surname><given-names>R. D.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Salmon</surname><given-names>D. P.</given-names></name><name><surname>Butters</surname><given-names>N.</given-names></name><name><surname>DeTeresa</surname><given-names>R.</given-names></name><name><surname>Hill</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>1991</year>). <article-title>Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment</article-title>. <source>Ann. Neurol</source>
<volume>30</volume>, <fpage>572</fpage>&#x02013;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1002/ana.410300410</pub-id><pub-id pub-id-type="pmid">1789684</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuminello</surname><given-names>E. R.</given-names></name><name><surname>Han</surname><given-names>S. D.</given-names></name></person-group> (<year>2011</year>). <article-title>The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations</article-title>. <source>Int. J. Alzheimers Dis</source>. <volume>2011</volume>:<fpage>726197</fpage>. <pub-id pub-id-type="doi">10.4061/2011/726197</pub-id><pub-id pub-id-type="pmid">21423560</pub-id></mixed-citation></ref></ref-list></back></article>